Your browser does not support JavaScript capabilities, which maybe required to display this page properly.


PDF FormatRequires Adobe Acrobat Reader

Table 13.6i

Immunosuppression Use for Antirejection Treatment from Transplant

to One Year Following Transplantation, 1998 to 2007

Recipients with Heart-Lung Transplants

  Year of Transplant
1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
Transplants 47 51 48 27 33 29 40 35 31 31
Tx with Antirejection Treatments 25 18 16 4 8 8 12 10 13 6
Antibodies Any in Category 20.0% 5.6% 18.8% 0.0% 0.0% 12.5% 16.7% 0.0% 38.5% 0.0%
Atgam/NRATG/NRATS 16.0% 0.0% 6.3% 0.0% 0.0% 12.5% 0.0% 0.0% 15.4% 0.0%
Thymoglobulin 4.0% 5.6% 0.0% 0.0% 0.0% 0.0% 16.7% 0.0% 15.4% 0.0%
Zenapax 0.0% 0.0% 12.5% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Simulect 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 7.7% 0.0%
Campath 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 7.7% 0.0%
Corticosteroids Any in Category 92.0% 94.4% 93.8% 100.0% 100.0% 62.5% 100.0% 100.0% 100.0% 100.0%
Steroids 92.0% 94.4% 93.8% 100.0% 100.0% 62.5% 100.0% 100.0% 100.0% 100.0%
Antimetabolites Any in Category 4.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Methotrexate 4.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%


Source: OPTN/SRTR Data as of May 4, 2009.

Individual drug percentages will not necessarily add up to the drug category percentages, as patients may be prescribed more than one drug within the same category.



PDF FormatRequires Adobe Acrobat Reader